Why the study?
Does pharmacomechanical catheter-directed thrombolysis reduce the risk of post-thrombotic syndrome in patients with proximal deep-vein thrombosis?
Does pharmacomechanical catheter-directed thrombolysis reduce the risk of post-thrombotic syndrome in patients with proximal deep-vein thrombosis?
Pharmacomechanical catheter-directed thrombolysis is hypothesized to reduce the risk of post-thrombotic syndrome in patients with proximal deep-vein thrombosis.
Answers are grounded in this paper and cite their sources.
Should not change DVT practice; leaves open whether pharmacomechanical thrombolysis reduces post-thrombotic syndrome.
The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheterdirected thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome.
No takes yet. Share an insight, caveat, or question.
Vedantham et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: